10-QHealthcare

Moderna, Inc.

MRNA · Period ending 2026-09-30 · Filed 2026-11-06 · Updated

In short

Moderna, Inc. (MRNA) has revenue down 39.9% to $1.9B and net income up 20.8% to -$2.8B year on year. Fisclear flags 4 high-severity risks, led by: Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$271.31

Market Cap

$109.8B

P/B

16.0x

Price ÷ book value

P/S (TTM)

43.5x

Price ÷ revenue per share

Beta

1.17

Moderate market correlation

52-Week Range

$22.28$271.31 now$271.48

Decision Context

Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

MRNA vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.1%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — MRNA

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Operating Cash Flow: -$1.9B (+37.6% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.

  • EPS (Diluted): $-7.26 (+21.8% YoY) — Negative EPS — the company recorded a loss on a per-share basis.

  • Net Income: -$2.8B (+20.8% YoY) — The company posted a net loss — total expenses exceeded total revenue.

◈

Weaknesses

  • Revenue: $1.9B (-39.9% YoY) — Revenue fell 40% — the company generated less from its core operations.

  • Total Assets: $12.3B (-12.8% YoY) — Total assets shrank 13% — the balance sheet contracted.

  • R&D spending is 161% of revenue — heavy investment in future growth, but also a drag on current profitability.

  • Stock is near its 52-week high (267.50) — the price reflects strong recent momentum, but entry risk is elevated at these levels.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly.

  • Revenue has declined for two consecutive years — a sustained downtrend that may signal structural or competitive headwinds.

  • Net loss of $2.8B — the company spent more than it earned. Investors should monitor the path to profitability.

  • Negative operating cash flow of $1.9B — the core business consumed more cash than it generated.

Year-over-Year Changes

Revenue

$1.9B

was $3.2B

−39.9%

Revenue fell 40% — the company generated less from its core operations.

Operating Cash Flow

-$1.9B

was -$3.0B

+37.6%

Negative operating cash flow — the business consumed more cash than it produced from operations.

EPS (Diluted)

$-7.26

was $-9.28

+21.8%

Negative EPS — the company recorded a loss on a per-share basis.

Net Income

-$2.8B

was -$3.6B

+20.8%

The company posted a net loss — total expenses exceeded total revenue.

Total Assets

$12.3B

was $14.1B

−12.8%

Total assets shrank 13% — the balance sheet contracted.

Risk Flags

4 high · 0 medium · 2 low
  • ⚠ High

    Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly.

  • ⚠ High

    Revenue has declined for two consecutive years — a sustained downtrend that may signal structural or competitive headwinds.

  • ⚠ High

    Net loss of $2.8B — the company spent more than it earned. Investors should monitor the path to profitability.

  • ⚠ High

    Negative operating cash flow of $1.9B — the core business consumed more cash than it generated.

  • ○ Low

    R&D spending is 161% of revenue — heavy investment in future growth, but also a drag on current profitability.

  • ○ Low

    Stock is near its 52-week high (267.50) — the price reflects strong recent momentum, but entry risk is elevated at these levels.

Technical Signals

Daily closes · 1-year data

Moderna, Inc.: common questions

Is Moderna, Inc. profitable?

No. Moderna, Inc. reported a net loss of $2.8B in its latest fiscal year (fiscal 2025).

Is Moderna, Inc.'s revenue growing?

No. Revenue fell 39.9% year on year, to $1.9B.

What is Moderna, Inc.'s P/E ratio?

Moderna, Inc. has no meaningful P/E ratio at the moment, because it lost money over the latest year. P/E only works when earnings are positive.

Does Moderna, Inc. pay a dividend?

No dividend is currently expected from Moderna, Inc., according to the latest market data.

What are the main risks for Moderna, Inc.?

Fisclear's checks flag 4 medium- or high-severity risks. The most serious: Revenue fell 40% year-over-year — a sharp decline that signals the business is contracting significantly.

Answers are generated from the figures in this report (updated 7 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — MRNA

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade MRNA

Links open broker research pages. Not an endorsement or recommendation.

Research Moderna, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.